SecBot SecBot
SECBOTREPLAY Home › Report › REGN

REGN · Regeneron and Telix announced a collaboration to co-develop and…

Regeneron Pharmaceuticals, Inc. · PRESS-RELEASE filed Apr 13, 2026 at 06:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 13, 2026 at 06:30 ET

Regeneron and Telix announced a collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Regeneron paying $40 million upfront for access to four initial programs. The 50/50 cost and profit-sharing model marks Regeneron's strategic entry into radiopharmaceuticals, combining its antibody expertise with Telix’s radiopharmaceutical infrastructure.

  • Regeneron pays Telix $40 million upfront for four initial radiopharmaceutical programs.
  • Partnership operates under a 50/50 cost and profit-sharing model, with co-development and co-commercialization rights.
  • Telix retains option to opt-out of co-funding and instead receive up to $535 million per program in milestones plus low double-digit royalties.
  • Regeneron gains option to expand the collaboration to four additional programs with further upfront payments.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access